Overseas ExpansionWhat we want to deliver
Our New Initiatives
- From Japan to the World -
The MEDIPAL Group is committed to developing therapeutic drugs for patients around the world suffering from ultra-rare diseases*.
*Diseases with an extremely small number of patients (defined as less than 1,000 patients in Japan by National Institutes of Biomedical Innovation, Health and Nutrition).
First, we will work on the development of drugs for the treatment of “fucosidosis” and “Mucopolysaccharidosis type IIIB” for which we have acquired from JCR Pharmaceuticals Co., Ltd. the rights for commercialization including research and development, manufacturing, and marketing.
Ultra-rare diseases have extremely small numbers of patients, making it difficult to develop and market new drugs.
The Medipal Group, aims to establish a system for the R&D and marketing of rare diseases medications in foreign countries, utilizing know-how in distribution and sales cultivated as a pharmaceutical wholesaler with our partner company JCR Pharma Co., Ltd.,
We will contribute to improving the quality of life of as many patients as possible by addressing unmet medical needs for ultra-rare diseases such as lysosomal storage disease.
MESSAGE
Developing businesses with high social value by leveraging our strengths
The MEDIPAL Group's main business has been wholesale in Japan, in order to further contribute to society and increase our corporate value, we will be working in the new field of global drug development.
The MEDIPAL Group has decided to progress commercialization several new drug candidates for ultra-rare diseases under development by JCR Pharmaceuticals Co., Ltd., and is currently working toward commercialization.
The development of new drug candidates for ultra-rare diseases is generally considered very challenging due to extremely small number of the patients. The MEDIPAL Group has begun global new drug development for these ultra-rare diseases. As a company involved in healthcare, we will continue to take on the challenge of creating social value for patients around the world who are anxiously awaiting the development of new drugs.
Toshihide Yoda
Senior Managing Director
MEDIPAL HOLDINGS CORPORATION
Provide new medications throughout the world
It is our desire to provide new medications to patients around the world.
Overseas Expansion
Our Focus